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Abstract
Introduction:  Felty's syndrome is an uncommon but severe extra-articular manifestation of
rheumatoid arthtitis. Felty's syndrome is characterized by the triad of rheumatoid arthtitis,
neutropenia, and splenomegaly. The lifetime risk of Felty's syndrome for a rheumatoid arthtitis
patient is less than 1% and there are only few case reports of Felty's syndrome with neutropenia
preceded clinical evidence of arthritis. We present a case which is atypical presentation of Felty's
syndrome without arthritis.
Case presentation: We present a case of 31-year-old man who presented with fever and skin
infection, found to have neutropenia. The work up showed splenomegaly and other evidences
support Felty's syndrome diagnosis without arthritis presentation.
Conclusion: Patients with unexplained, continuous neutropenia without arthristis but with high
level of rheumatoid factor and positive antibodies to cyclic citrullinated peptides should be
suspected of developing Felty's syndrome as an initial presentation of rheumatoid arthtitis.
Case presentation
31-year-old Caucasian male with no significant past med-
ical history presented with fever of 102 F, chills and 4 cen-
timeters painful redness induration at right inguinal
region for 1 week. He denied chest pain, shortness of
breath, palpitations, cough, headache, dizziness, nausea,
vomiting, abdominal pain, bowel or urinary symptoms,
weight or appetite changes. He has no drug use, sick con-
tacts, recent travel, exposure to tuberculosis and unpro-
tected sexual exposure. He does not smoke. He drinks beer
occasionally on weekends but denies illicit drug use. He
works in a food store with no direct raw food contact. He
has no history of sexually transmitted diseases. His pater-
nal aunt has Rheumatoid Arthritis (RA).
Physical examination demonstrated mild pallor, cellulitis
at right inguinal area and left inguinal lymphadenopahy.
Arthritis and rheumatoid nodules were absent.
Hemoglobin was 10.6 g/dL, hematocrit was 30% with
MCV of 86.4, white blood cell count was 1.2 × 109/L with
absolute neutrophil count of 450 (0.45 × 109/L) and
platelet was 221 × 109/L. Peripheral blood smear showed
no significant abnormality with normal appearing white
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blood cells with few toxic granulations. Bone marrow
biopsy showed normocellular and maturing trilineage
hematopoiesis. Flow cytometry showed no evidence of
lymphoproliferative disorder. He had negative tests for
Syphilis, HIV, hepatitis B and hepatitis C. Monospot test,
PPD skin test, ANA panel and Parvovirus B19 also were
negative. Erythrocyte sedimentation rate was 50 mm/hr.
C-reactive protein was 60.2 mg/l. Lymph node biopsy
from left inguinal node revealed benign reactive lymph
node. Abdominal computed tomography showed
splenomegaly with triangular hypodense lesion at the lat-
eral aspect of the mid portion of the spleen (abcess versus
infarct). Negative Galium scan confirmed the diagnosis of
splenic infarct. Rheumatoid factor (RF) was positive with
titer of 1:640. Antibodies to cyclic citrullinated peptides
(anti-CCP) were positive >250. Joint x-rays including
wrists, hands, knees, ankles, feet showed no evidence of
erosions.
The provisional diagnosis was Felty's Syndrome (FS).
Treatment was initiated with methotrexate and granulo-
cyte colony-stimulating factor (G-CSF). The neutropenia
initially corrected and the erythrocyte sedimentation rate
and C-reactive protein improved significantly. However, 2
weeks after cessation of G-CSF therapy the neutrophil
count declined and second course of G-CSF was given.
Overall treatment was tolerated well, except for the devel-
opment of mild fever, mild arthritis and transient throm-
bocytopenia which are known side effects of G-CSF
treatment. He currently remains on methotrexate with
reasonable control of his symptoms.
Discussion
RA is a chronic inflammatory arthritis with significant
extra-articular manifestations. FS is a severe extra-articular
feature of RA. FS is characterized by the triad of RA, neu-
tropenia, and splenomegaly. The lifetime risk of FS for a
RA patient is less than 1% [1]. Over 95% of FS patients are
positive for RF with high titers [1,2]. FS usually develops
after a long course of RA [2]. Arthritis almost always
appears first and typically has been present for 10 years or
more before neutropenia is recognized [3]. The articular
disease in FS is usually severe in terms of both erosions
and deformity [2]. In very rare cases, neutropenia appears
before or with no arthritis and this patient is a representa-
tion of the latter [4-7].
In this case, the patient presented with skin infection in
neutropenic setting. The most common infections affect
the skin, mouth, and upper and lower respiratory tract [2].
Neutropenia and splenomegaly with elevated erythrocyte
sedimentation rate, elevated C-reactive protein and ane-
mia of chronic disease pointed toward connective tissue
disorder. The clues that lead to the diagnosis of RA were
high-titer RF and positive anti-CCP. Anti-CCP has very
high specificity for RA-96% [8]. Combination of RF and
anti-CCP has specificity of 99.5% for RA and highly pre-
dictive for development of erosions at 5 years of disease
[8]. This case is an atypical presentation of FS because the
lack of severe long lasting course of erosive RA. There is no
specific diagnostic test for FS. It is a clinical diagnosis in
RA with unexplained neutropenia and splenomegaly.
Patient was started treatment for presumed FS with meth-
otrexate and G-CSF. Patient subsequently developed joint
pain and swelling with less than 30 minutes stiffness in
proximal interphalangeal joints, metacarpophalangeal
joints, wrists, and knees. The non-specific arthritis was
most likely due to the side effect of G-CSF as it disap-
peared after the medication was temporarily stopped.
However, the patient needs to be followed closely, as
repeat episode of arthritis in the future can be due to RA
rather than G-CSF alone.
Treatment of neutropenia is mainly comprised of disease-
modifying anti-rheumatic drugs (DMARDs) including
methotrexate, hydroxychloroquine, auranofin, penicilla-
mine, glucocorticoids, and G-CSF. The first choice for
treating both neutropenia and arthritis is methotrexate
which is safe, effective and well tolerated in these patients
[9]. Recently, there has been an interest in the biologic
agent rituximab in the treatment of FS but only a few cases
has been reported [10]. Leflunomide, sulfasalazine and
cyclophosphamide also have been reported but the expe-
rience is very limited [11]. The controlled studies of differ-
ent treatment modalities are not available because of the
rarity of this syndrome. Splenectomy produces a long-
term hematologic response in 80% of patients but is usu-
ally reserved at the end of the treatment algorithm for
treatment-resistant cases. [12].
G-CSF has no effect on the activity of RA but is effective
and generally well-tolerated for the treatment of neutro-
penia due to FS [13]. Quick improvement in neutropenia
has been reported with G-CSF [14]. G-CSF has been used
as treatment for FS but with the known side effects of
fever, thrombocytopenia and arthritis, all of which this
patient had after receiving G-CSF [13]. The sustained gran-
ulopoietic response has been reported in some cases but
the neutrophil count often declines when growth factor
treatment is stopped but generally stabilized at a level that
exceeded the pretreatment count [13]. Patients who toler-
ate G-CSF and have good hematologic responses may be
candidates for prolonged therapy. This patient has been
receiving G-CSF for maintenance of white blood cell
count.
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